Preclinical Development of SHR-1819, a Potent Humanized IL-4Rα Antibody for Treating Type 2 Inflammatory Diseases
Guolin Zhao,1,2 Zhijun Wang,1,2 Jun Zhang,1,2 Yuan Lin,1,2 Tang Zhou,1,2 Kaili Liu,1,2 Changyong Yang,1 Cheng Liao1 1Department of Preclinical Research and Development, Jiangsu Hengrui Pharmaceuticals Co., Ltd., Lianyungang, Jiangsu, People's Republic of China; 2Department of Preclinical Resear...
Saved in:
Main Authors: | Zhao G (Author), Wang Z (Author), Zhang J (Author), Lin Y (Author), Zhou T (Author), Liu K (Author), Yang C (Author), Liao C (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2024-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Safety, pharmacokinetics, and pharmacodynamics of anti‐IL‐4Rα antibody SHR‐1819 in healthy subjects: A randomized, controlled phase I study
by: Na Li, et al.
Published: (2024) -
Features of the alpha-cell population organization in pancreas of spontaneously hypertensive rats (SHR)
by: T. V. Abramova, et al.
Published: (2017) -
Reminiscences, 1819-1899
by: Howe, Julia Ward, 1819-1910 -
Preclinical characterization of the ADME properties of a surrogate anti-IL-36R monoclonal antibody antagonist in mouse serum and tissues
by: Kip P. Conner, et al.
Published: (2020) -
Effect of Efavirenz on the Pharmacokinetics of SHR6390 in Healthy Volunteers
by: Wang J, et al.
Published: (2024)